Solvonis Therapeutics PLC (LSE:SVNS) chairman Dennis Purcell will speak at Lucid Capital Markets’ biotech leadership event on 17 July.
Purcell, with over 30 years in life sciences investment and $15 billion deployed through Aisling Capital, will discuss leadership, innovation, and capital strategy in biotech.
His participation highlights Solvonis’s strong leadership as it advances its AI-driven drug discovery platform targeting addiction and mental health disorders. The event takes place at 2:00pm ET / 7:00pm BST.